News Releases

June 12, 2019
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines
– Fuels development of Synlogic’s growing pipeline of novel living medicines with technology access and $80.0 million equity investment at a premium – – Applies Ginkgo’s high-throughput synthetic biology platform services to human therapeutics – – Synlogic to host a conference call at 8:00 am ET...
May 22, 2019
Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic...
May 9, 2019
Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update
– Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial...
May 2, 2019
Synlogic Announces First Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market...
April 30, 2019
Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Synlogic’s robust and reproducible lyophilization process provides a solid formulation of SYNB1618 with improved quality attributes, stability and minimal loss of viability compared to liquid formulation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Synlogic, Inc....
April 15, 2019
Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 15, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of...
April 9, 2019
Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 9, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy , M.D., as Chief Scientific Officer. Dr....
April 2, 2019
Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019 , in...
March 13, 2019
Synlogic to Webcast Presentation at the Oppenheimer 29th Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- Synlogic (Nasdaq:SYBX) announced today that Caroline Kurtz , Ph.D., Synlogic’s Head of Metabolism, will provide a corporate update at Oppenheimer’s 29th Annual Healthcare Conference at 3:20 pm ET on Wednesday, March 20, 2019 , in New York City ....
March 12, 2019
Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
– Ended 2018 with approximately $123 million in cash and investments, which provides runway through 2020 – – Clinical trial readouts expected in mid-2019 from two Synthetic Biotic ™ medicines and first IND application expected from Synlogic’s immuno-oncology platform in second half of 2019 – –...
March 6, 2019
Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its...
March 5, 2019
Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2018 financial results before the...
Displaying 73 - 84 of 156